熱門詞： 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥
熱門詞： 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥
Visterra Visterra
Visterra發(fā)現(xiàn)和開發(fā)新型抗體應(yīng)對重大傳染病的預(yù)防和治療。
Visterra discovers and develops novel antibodies for the prevention and treatment of major infectious diseases. The company’s proprietary antibody engineering technology generates unique structural information that identifies novel target epitopes (sites recognized by antibodies) and guides the design of antibodies which specifically target these epitopes to effectively combat disease. The company’s lead antibody product candidate, VIS410, is a broad spectrum monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. The company is building a proprietary pipeline of novel antibodies in infectious disease, and continuing to expand its disease area focus through strategic partnerships. Visterra was founded based on scientific work developed in the laboratory of Dr. Ram Sasisekharan and licensed from MIT. The company is currently backed by Polaris Partners, Flagship Ventures, Lux Capital, the Bill & Melinda Gates Foundation, and Omega Funds.
知識產(chǎn)權(quán)侵權(quán)投訴：不生產(chǎn)任何產(chǎn)品所有產(chǎn)品均來自產(chǎn)品的生產(chǎn)廠商、代理商、經(jīng)銷商，如有侵權(quán)請聯(lián)系：400-006-7520 ，我們會在第一時間處理
本網(wǎng)站所有產(chǎn)品與藥品無關(guān)
滬公網(wǎng)安備31011502016460號
